T1	CHEM 146 155	ritonavir
#1	AnnotatorNotes T1	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T2	CHEM 289 298	ritonavir
#2	AnnotatorNotes T2	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T3	CHEM 279 288	darunavir
#3	AnnotatorNotes T3	C1435444; darunavir; Organic Chemical · Pharmacologic Substance
T4	PROC 313 387	Estudio abierto aleatorizado de fase II/III, multicéntrico, con dos grupos
T5	DISO 403 412	toxicidad
#4	AnnotatorNotes T5	C0600688; Toxic effect; Injury or Poisoning
T6	CHEM 572 575	DRV
T7	PROC 451 477	terapias antirretrovirales
#5	AnnotatorNotes T7	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T8	CHEM 511 523	elvitegravir
#6	AnnotatorNotes T8	C2606637; elvitegravir; Organic Chemical · Pharmacologic Substance
T9	CHEM 551 560	darunavir
#7	AnnotatorNotes T9	C1435444; darunavir; Organic Chemical · Pharmacologic Substance
T10	CHEM 561 570	ritonavir
#8	AnnotatorNotes T10	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T11	DISO 604 627	infectados por el VIH-1
#9	AnnotatorNotes T11	C2363741; HIV-1 infection; Disease or Syndrome
T12	CHEM 123 135	elvitegravir
#10	AnnotatorNotes T12	C2606637; elvitegravir; Organic Chemical · Pharmacologic Substance
T13	CHEM 136 145	darunavir
#11	AnnotatorNotes T13	C1435444; darunavir; Organic Chemical · Pharmacologic Substance
T14	DISO 106 109	VIH
#12	AnnotatorNotes T14	C0458074; Human immunodeficiency virus (HIV) status; Finding
T15	DISO 249 252	VIH
#13	AnnotatorNotes T15	C0458074; Human immunodeficiency virus (HIV) status; Finding
T16	CHEM 525 528	EVG
#14	AnnotatorNotes T16	C2606637; elvitegravir; Organic Chemical · Pharmacologic Substance
T17	DISO 672 692	Infeccion por el VIH
#15	AnnotatorNotes T17	C0019693; HIV Infections; Disease or Syndrome
T18	CHEM 266 278	elvitegravir
#16	AnnotatorNotes T18	C2606637; elvitegravir; Organic Chemical · Pharmacologic Substance
T19	Date 13 17	2013
T21	LIVB 113 118	niños
#17	AnnotatorNotes T21	C0008059; Child; Age Group
T23	LIVB 256 261	niños
#18	AnnotatorNotes T23	C0008059; Child; Age Group
T24	Date 442 450	actuales
T25	LIVB 582 603	pacientes pediátricos
#19	AnnotatorNotes T25	C0030705; Patients; Patient or Disabled Group + C0008059; Child; Age Group
T27	LIVB 689 692	VIH
#20	AnnotatorNotes T27	C0019682; HIV; Virus
T28	LIVB 699 719	poblacion pediatrica
#21	AnnotatorNotes T28	C1257890; Population; Population Group + C0008059; Child; Age Group
T20	LIVB 622 627	VIH-1
#22	AnnotatorNotes T20	C0019704; HIV-1; Virus
T22	LIVB 642 647	viral
#23	AnnotatorNotes T22	C0042776; Virus; Virus
T26	Observation 632 647	supresión viral
T29	Observation 92 101	supresión
T30	Observation 235 244	supresión
A1	Population_data T21 Age
A2	Population_data T23 Age
A3	Population_data T25 Age
A4	Population_data T28 Age
#24	AnnotatorNotes T4	C1519042; Phase II/III Trial; Research Activity + C1709323; Open Label Study; Research Activity + C1096776; Multicenter Study; Research Activity + C2826345; Parallel Study; Research Activity  + C0034656; Randomization; Research Activity
#25	AnnotatorNotes T6	C1435444; darunavir; Organic Chemical · Pharmacologic Substance
#26	AnnotatorNotes T24	C0521116; Current (present time); Temporal Concept 
#27	AnnotatorNotes T29	C3888663; Sustained viral response; Finding (?)
#28	AnnotatorNotes T30	C3888663; Sustained viral response; Finding (?)
R1	Experiences Arg1:T23 Arg2:T15	
R2	Experiences Arg1:T21 Arg2:T14	
R3	Experiences Arg1:T21 Arg2:T29	
R4	Experiences Arg1:T23 Arg2:T30	
R5	Experiences Arg1:T21 Arg2:T12	
R6	Combined_with Arg1:T12 Arg2:T13	
R7	Combined_with Arg1:T13 Arg2:T1	
R8	Experiences Arg1:T23 Arg2:T18	
R9	Combined_with Arg1:T18 Arg2:T3	
R10	Combined_with Arg1:T3 Arg2:T2	
R11	Overlap Arg1:T7 Arg2:T24	
R12	Causes Arg1:T7 Arg2:T5	
R13	Combined_with Arg1:T8 Arg2:T9	
R14	Combined_with Arg1:T9 Arg2:T10	
R15	Combined_with Arg1:T8 Arg2:T6	
R16	Combined_with Arg1:T16 Arg2:T9	
R17	Combined_with Arg1:T16 Arg2:T6	
R18	Experiences Arg1:T25 Arg2:T5	
R19	Experiences Arg1:T25 Arg2:T7	
R20	Experiences Arg1:T25 Arg2:T11	
R21	Causes Arg1:T20 Arg2:T11	
R22	Experiences Arg1:T25 Arg2:T26	
R23	Causes Arg1:T22 Arg2:T11	
#29	AnnotatorNotes T26	C3888663; Sustained viral response; Finding (?)
R24	Causes Arg1:T27 Arg2:T17	
R25	Experiences Arg1:T28 Arg2:T17	
A5	Experiencer T21 Patient
A6	Experiencer T23 Patient
A7	Experiencer T25 Patient
A8	Experiencer T28 Patient
